Berglund, Peter

An Alphavirus -derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates

Erasmus, J. H., Khandhar, A. P., O’Connor, M. A., Walls, A. C., Hemann, E. A., Murapa, P., Archer, J., Leventhal, S., Fuller, J. T., Lewis, T. B., et al. (2020) · Science Translational Medicine

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 241

Enhancing immune responses using suicidal DNA vaccines

Berglund, P., Smerdou, C., Fleeton, M. N., Tubulekas, L., & Liljeström, P. (1998) · Nature Biotechnology

Influenza Virus Research StudiesImmunotherapy and Immune Responses

Cited by 229

Self-replicating Semliki Forest virus RNA as recombinant vaccine

Zhou, X., Berglund, P., Rhodes, G., Parker, S. E., Jondal, M., & Liljeström, P. (1994) · Vaccine

Influenza Virus Research StudiesVirology and Viral Diseases

Cited by 193

Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus

Fleeton, M. N., Chen, M., Berglund, P., Rhodes, G., Parker, S. E., Murphy, M., Atkins, G. J., & Liljeström, P. (2001) · The Journal of Infectious Diseases

Influenza Virus Research StudiesImmunotherapy and Immune Responses

Cited by 157

Amplifying RNA Vaccine Development

Fuller, D. H., & Berglund, P. (2020) · New England Journal of Medicine

Immunotherapy and Immune ResponsesRNA Interference and Gene Delivery

Cited by 116

Generation of cytotoxic and humoral immune responses by nonreplicative recombinant Semliki Forest virus.

Zhou, X., Berglund, P., Zhao, H., Liljeström, P., & Jondal, M. (1995) · Proceedings of the National Academy of Sciences

Influenza Virus Research StudiesImmunotherapy and Immune Responses

Cited by 115

Long-term cognitive impairments and attentional deficits in patients with Cushing’s disease and cortisol-producing adrenal adenoma in remission

Ragnarsson, O., Berglund, P., Eder, D. N., & Johannsson, G. (2012) · The Journal of Clinical Endocrinology & Metabolism

Pituitary Gland Disorders and TreatmentsAdrenal and Paraganglionic Tumors

Cited by 111

A localizing nanocarrier formulation enables multi-target immune responses to multivalent replicating RNA with limited systemic inflammation

Kimura, T., Leal, J. M., Simpson, A., Warner, N. L., Berube, B. J., Archer, J. F., Park, S., Kurtz, R., Hinkley, T., Nicholes, K., et al. (2023) · Molecular Therapy

RNA Interference and Gene DeliveryImmunotherapy and Immune Responses

Cited by 52

LV305, a dendritic cell-targeting integration-deficient ZVex TM -based lentiviral vector encoding NY-ESO-1, induces potent anti-tumor immune response

Albershardt, T. C., Campbell, D. J., Parsons, A. J., Slough, M. M., ter Meulen, J., & Berglund, P. (2016) · Molecular Therapy - Oncolytics

Immunotherapy and Immune ResponsesVirus-based gene therapy research

Cited by 38

Toll-Like Receptor 4 Agonist Injection With Concurrent Radiotherapy in Patients With Metastatic Soft Tissue Sarcoma: A Phase 1 Nonrandomized Controlled Trial

Seo, Y. D., Lu, H., Black, G., Smythe, K., Yu, Y., Hsu, C., Ng, J., Hermida de Viveiros, P., Warren, E. H., Schroeder, B. A., et al. (2023) · JAMA Oncology

Sarcoma Diagnosis and TreatmentImmunotherapy and Immune Responses

Cited by 31

ZVex™, a dendritic-cell-tropic lentivector, primes protective antitumor T cell responses that are significantly boosted using heterologous vaccine modalities

Leleux, J. A., Albershardt, T. C., Parsons, A. J., ter Meulen, J., & Berglund, P. (2020) · Vaccine

Immunotherapy and Immune ResponsesVirus-based gene therapy research

Cited by 5